×

Amicus Therapeutics Announces Presentations and Posters at Lysosomal Disease Network WORLD Symposium

CRANBURY, N.J., Jan. 30, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that three oral presentations and five posters highlighting its development programs for lysosomal storage diseases will be included at the 10th Annual Lysosomal Disease Network WORLD Symposium (LDN WORLD), to be held February 10-14, 2014 in San Diego, CA.

Oral Platform Presentations:

Pompe Disease:

  • Chemical Conjugation of Targeting Peptide to ERTs Improve Receptor Binding and Substrate Clearance in Mouse Models of Disease – Hung Do, PhD, Amicus Therapeutics, Inc. (Wednesday, February 12 at 2:45 p.m. PT)

Fabry Disease:

  • Phase 3 Study (FACETS) of Migalastat HCl for Fabry Disease: Post hoc GLA Mutation-Based Identification of Subjects Likely to Show a Drug Effect – Jeffrey P. Castelli, PhD, Amicus Therapeutics, Inc. (Thursday, February 13 at 11:15 a.m. PT)

Gaucher Disease:

  • Glucosylceramide and Glucosylsphingosine Quantitation by Liquid Chromatography-Tandem Mass Spectrometry to Enable Studies of Neuronopathic Gaucher Disease – Rick Hamler, Amicus Therapeutics, Inc. (Tuesday, February 11 at 10:30 a.m. PT)

Posters: Tuesday, February 11 - Thursday, February 13, 4:00-6:00 p.m. PT

Pompe Disease:

  • Chemical Conjugation of Targeting Peptide to ERTs Improve Receptor Binding and Substrate Clearance in Mouse Models of Disease – Russell Gotschall, Amicus Therapeutics, Inc.
  • Subcutaneous Administration of Recombinant Human Acid Alpha-Glucosidase Co-formulated with the Pharmacological Chaperone AT2220 Leads to Lysosomal Uptake of rhGAA and Glycogen Reduction in Disease-relevant Tissues of Pompe Mice – Yi Lun, Amicus Therapeutics, Inc.
  • Strategy to Assess the Effect of Duvoglustat Co-administered with Alglucosidase Alfa Infusion on the Immune Response to Enzyme Replacement Therapy for Pompe Disease – Xiaoyang Wu, Amicus Therapeutics, Inc.
  • Liquid Chromatography-Tandem Mass Spectrometry Determination of AT2220 in Rodent Plasma and Tissues – Leo B. Dungan, Amicus Therapeutics, Inc.

Fabry Disease:

  • Phase 3 Study (FACETS) of Migalastat HCl for Fabry Disease: Post hoc GLA Mutation-Based Identification of Subjects Likely to Show a Drug Effect – Elfrida R. Benjamin, Amicus Therapeutics, Inc.

About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.

CONTACT: Investors/Media: Sara Pellegrino spellegrino@amicusrx.com (609) 662-5044Source:Amicus Therapeutics, Inc.